Solventum Corporation/$SOLV
1D1W1MYTD1Y5YMAX
Capital at risk
About Solventum Corporation
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
- Ticker
- $SOLV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,584
- Headquarters
- Eagan, United States
- Website
- www.solventum.com
SOLV Metrics
BasicAdvanced
$15B
11.00
$8.19
0.67
-
Price and volume
Market cap
$15B
Beta
0.67
52-week high
$94.16
52-week low
$62.38
Average daily volume
1.2M
Financial strength
Current ratio
1.021
Quick ratio
0.501
Long term debt to equity
99.729
Total debt to equity
110.313
Interest coverage (TTM)
2.14%
Profitability
EBITDA (TTM)
1,139
Gross margin (TTM)
54.06%
Net profit margin (TTM)
17.26%
Operating margin (TTM)
7.62%
Effective tax rate (TTM)
15.45%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.42%
Return on equity (TTM)
33.96%
Valuation
Price to earnings (TTM)
10.998
Price to revenue (TTM)
1.886
Price to book
3.19
Price to tangible book (TTM)
-4.74
Price to free cash flow (TTM)
-132.798
Free cash flow yield (TTM)
-0.75%
Free cash flow per share (TTM)
-0.679
Growth
Revenue change (TTM)
-0.93%
Earnings per share change (TTM)
275.10%
3-year revenue growth (CAGR)
0.85%
3-year earnings per share growth (CAGR)
4.05%
What the Analysts think about SOLV
Analyst ratings (Buy, Hold, Sell) for Solventum Corporation stock.
Analyst projections of the future price of Solventum Corporation stock.
Bulls say / Bears say
Solventum’s Q1 2026 sales of $2.007 billion beat consensus of $1.967 billion and adjusted EPS of $1.48 topped estimates of $1.35, underscoring robust demand and operational execution. (Reuters)
The company raised its full-year 2026 adjusted EPS guidance to the high end of $6.40–$6.60 per share, reflecting confidence in continued momentum in its core wound care and sterilization businesses. (Reuters)
Nelson Peltz’s Trian Fund, which owns nearly 5% of Solventum, has urged the company to divest non-core assets and optimize costs, potentially accelerating strategic focus and value creation. (Reuters)
Solventum’s share price has declined approximately 30% since its spin-off, underperforming peers and signaling investor skepticism about its standalone valuation. (Bloomberg)
GAAP net income plunged 90.5% year-over-year in Q1 2026 to $13 million as significant spin-off and restructuring charges weighed on profitability. (Reuters)
Approximately $125 million in customer orders was pulled forward into Q2 ahead of an ERP system cutover, which is expected to reverse in Q3 and result in a projected 3–4% sales contraction, raising questions about growth sustainability. (Reuters via Bitget News)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SOLV Financial Performance
Revenues and expenses
SOLV Earnings Performance
Company profitability
Upcoming events
No upcoming events
SOLV News
AllArticlesVideos
Funds containing SOLV
AllEURGBPUSD
Fund name | Fund size | $SOLV weighting |
|---|---|---|
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.21% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.21% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.20% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.